<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03926819</url>
  </required_header>
  <id_info>
    <org_study_id>HBI-CP-01-001</org_study_id>
    <secondary_id>2R44HL131065</secondary_id>
    <nct_id>NCT03926819</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Open Labeled Single Ascending Dose Followed by Multiple Dose Safety and Pharmacokinetic Study of HBI-002 Carbon Monoxide Oral Liquid Drug Product in Healthy Adult Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hillhurst Biopharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Hillhurst Biopharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, open label Phase 1 clinical trial in normal adult subjects to assess&#xD;
      safety, tolerability, pharmacokinetics, and pharmacodynamics of HBI-002, an orally&#xD;
      administered liquid containing carbon monoxide, with single ascending doses (SAD), followed&#xD;
      by multiple dose with doses daily for 7 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 1 to 7 days post last dose.</time_frame>
    <description>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum COHb Concentration (Cmax).</measure>
    <time_frame>Blood samples will be drawn on Day 1 immediately before and after dosing at 30, 60, 90, 120 minutes and at 3, 4, 5, 6, 24, 48, and 72 hours</time_frame>
    <description>Maximum COHb Concentration (Cmax).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Laboratory Test Abnormalities</measure>
    <time_frame>Day 1 to 7 days post last dose.</time_frame>
    <description>Number of Participants With Laboratory Test Abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum COHb Concentration (Tmax).</measure>
    <time_frame>Blood samples will be drawn on Day 1 immediately before and after dosing at 30, 60, 90, 120 minutes and at 3, 4, 5, 6, 24, 48, and 72 hours</time_frame>
    <description>Time to Maximum COHb Concentration (Tmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-Life (T1/2)</measure>
    <time_frame>Blood samples will be drawn on Day 1 immediately before and after dosing at 30, 60, 90, 120 minutes and at 3, 4, 5, 6, 24, 48, and 72 hours</time_frame>
    <description>Elimination Half-Life (T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>Blood samples will be drawn on Day 1 immediately before and after dosing at 30, 60, 90, 120 minutes and at 3, 4, 5, 6, 24, 48, and 72 hours</time_frame>
    <description>Area Under the Curve (AUC)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Anemia, Sickle Cell</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HBI-002</intervention_name>
    <description>Oral liquid carbon monoxide drug product.</description>
    <arm_group_label>Multiple Ascending Dose</arm_group_label>
    <arm_group_label>Single Ascending Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Non-smoker (no use of tobacco or marijuana products within 3 months of screening)&#xD;
&#xD;
          2. Subjects must be healthy as defined by:&#xD;
&#xD;
               1. the absence of clinically significant hematological, renal, endocrine, pulmonary,&#xD;
                  gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic or allergic&#xD;
                  disease, as determined by the Investigator.&#xD;
&#xD;
               2. the absence of current clinically relevant abnormalities&#xD;
&#xD;
               3. the absence of clinically significant illness and/or surgery within 4 weeks prior&#xD;
                  to dosing.&#xD;
&#xD;
          3. Negative urine pregnancy test for females&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Anemia of any cause.&#xD;
&#xD;
          2. Homozygous or heterozygous hemoglobinopathy.&#xD;
&#xD;
          3. Blood transfusion within six weeks prior to the first administration of study drug.&#xD;
&#xD;
          4. Exposure to any live vaccine within 28 days prior to study drug treatment.&#xD;
&#xD;
          5. History of febrile or infective illness within10 days preceding study drug treatment.&#xD;
&#xD;
          6. Weight loss or gain of more than 5 kg within 3 months of screening.&#xD;
&#xD;
          7. History of alcohol abuse or dependence or regular use of alcohol within six months&#xD;
             prior to the screening visit (defined as more than 14 units of alcohol per week; 1&#xD;
             Unit= 150 mL wine, 360 mL beer or 45 mL of 40% alcohol)&#xD;
&#xD;
          8. History of pulmonary infiltrate or pneumonia within 6 months before screening or&#xD;
             pulmonary/bronchial infection within 2 weeks of screening.&#xD;
&#xD;
          9. History of cancer with the exception of adequately treated basal cell or squamous cell&#xD;
             carcinoma of the skin more than 1 year prior.&#xD;
&#xD;
         10. History of drug abuse or dependence.&#xD;
&#xD;
         11. Use of prescription drugs within 7 days or 5 half-lives (whichever is longer) prior to&#xD;
             the first dose of study medication. Herbal and vitamin supplements must be&#xD;
             discontinued 28 days prior to the first dose of study medication.&#xD;
&#xD;
         12. Unwilling or unable to comply with the requirements of the protocol.&#xD;
&#xD;
         13. Any coincident disease or condition that in the opinion of the investigator would make&#xD;
             the subject inappropriate for entry into the study or will confound the assessment of&#xD;
             safety&#xD;
&#xD;
         14. Pregnancy or breast feeding.&#xD;
&#xD;
         15. Treatment with an investigational drug within the longer of 30 days or five half-lives&#xD;
             of an investigational agent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 22, 2019</study_first_submitted>
  <study_first_submitted_qc>April 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia, Sickle Cell</keyword>
  <keyword>Anemia, Hemolytic, Congenital</keyword>
  <keyword>Anemia, Hemolytic</keyword>
  <keyword>Anemia</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Hemoglobinopathies</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <keyword>Carbon Monoxide</keyword>
  <keyword>CO</keyword>
  <keyword>Heme Oxygenase</keyword>
  <keyword>HO-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

